scholarly journals Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland

Vaccine ◽  
2018 ◽  
Vol 36 (15) ◽  
pp. 1934-1940 ◽  
Author(s):  
Hanna Rinta-Kokko ◽  
Arto A. Palmu ◽  
Kari Auranen ◽  
J. Pekka Nuorti ◽  
Maija Toropainen ◽  
...  
2019 ◽  
Vol 70 (12) ◽  
pp. 2607-2615
Author(s):  
Kelley N Meder ◽  
Sanjay Jayasinghe ◽  
Frank Beard ◽  
Aditi Dey ◽  
Martyn Kirk ◽  
...  

Abstract Background Universal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Australian children in 2001 and all children in 2005, changing to 13-valent PCV (PCV13) in 2011. We used laboratory data for invasive pneumococcal disease (IPD) and coded hospitalizations for noninvasive pneumococcal community-acquired pneumonia (PnCAP) to evaluate long-term impact. Methods Annual incidence (per 100 000 population) was calculated for age-specific total IPD, PCV13 non–7-valent PCV (PCV7) serotypes, and PnCAP by Indigenous status. Incidence in the pre–universal PCV7 (2002–2004), early PCV7 (2005–2007), pre-PCV13 (2008 to mid-2011), and post-PCV13 (mid-2011 to 2016) periods was used to calculate incidence rate ratios (IRRs). Results In the total population, all-age incidence of IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR, 0.61 [95% confidence interval {CI}, .59–.63]) but for PnCAP declined among ages <1 year (IRR, 0.34 [95% CI, .25–.45]) and 1–4 years (IRR, 0.50 [95% CI, .43–.57]) but increased significantly among age ≥5 years (IRRs, 1.08–1.14). In Indigenous people, baseline PCV13 non-PCV7 IPD incidence was 3-fold higher, amplified by a serotype 1 epidemic in 2011. By 2015–2016, although incidence of IPD and PnCAP in children aged <5 years decreased by 38%, neither decreased in people aged ≥5 years. Conclusions Fifteen years post-PCV and 5 years post-PCV13, direct and indirect impact on IPD and PnCAP differed by age and between Indigenous and non-Indigenous people, with potential implications for long-term PCV impact in comparable settings. Fifteen years after pneumococcal conjugate vaccine (PCV) introduction and 5 years post-PCV13, direct and indirect impact on invasive pneumococcal disease and pneumococcal community-acquired pneumonia differed by age and between Indigenous and non-Indigenous people, with potential implications for long-term PCV impact in comparable settings.


2019 ◽  
Vol 38 (9) ◽  
pp. 967-973
Author(s):  
Sanjay Jayasinghe ◽  
Bette Liu ◽  
Heather Gidding ◽  
Amy Gibson ◽  
Clayton Chiu ◽  
...  

Vaccine ◽  
2019 ◽  
Vol 37 (43) ◽  
pp. 6558-6565 ◽  
Author(s):  
Stefan M.T. Vestjens ◽  
Elisabeth A.M. Sanders ◽  
Bart J. Vlaminckx ◽  
Hester E. de Melker ◽  
Arie van der Ende ◽  
...  

2017 ◽  
Vol 49 (5) ◽  
pp. 365-372 ◽  
Author(s):  
Hans Kristian Floeystad ◽  
Are Holm ◽  
Leiv Sandvik ◽  
Didrik Frimann Vestrheim ◽  
Bjorn Brandsaeter ◽  
...  

Vaccine ◽  
2008 ◽  
Vol 26 (26) ◽  
pp. 3277-3281 ◽  
Author(s):  
Didrik F. Vestrheim ◽  
Øistein Løvoll ◽  
Ingeborg S. Aaberge ◽  
Dominique A. Caugant ◽  
E. Arne Høiby ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document